Wall Street Zen Upgrades Prenetics Global (NASDAQ:PRE) to Hold

Prenetics Global (NASDAQ:PRE) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts have also weighed in on the company. Benchmark increased their target price on Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.25.

Prenetics Global Stock Performance

Shares of PRE opened at $20.20 on Friday. The firm has a market cap of $340.77 million, a P/E ratio of -4.86 and a beta of 0.26. Prenetics Global has a 52 week low of $7.18 and a 52 week high of $23.63. The firm’s 50-day simple moving average is $19.05 and its 200 day simple moving average is $18.88.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings data on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The firm had revenue of $46.49 million during the quarter, compared to the consensus estimate of $49.85 million. As a group, equities analysts forecast that Prenetics Global will post -1.86 earnings per share for the current year.

Institutional Trading of Prenetics Global

A number of institutional investors have recently bought and sold shares of PRE. State of Wyoming bought a new position in shares of Prenetics Global during the first quarter worth approximately $48,000. Wells Fargo & Company MN acquired a new stake in shares of Prenetics Global in the fourth quarter valued at approximately $47,000. JPMorgan Chase & Co. acquired a new stake in shares of Prenetics Global in the third quarter valued at approximately $65,000. Operose Advisors LLC bought a new stake in shares of Prenetics Global in the second quarter valued at approximately $129,000. Finally, Stevens Capital Partners boosted its stake in shares of Prenetics Global by 54.6% in the first quarter. Stevens Capital Partners now owns 28,147 shares of the company’s stock valued at $544,000 after buying an additional 9,940 shares during the period. Institutional investors own 25.01% of the company’s stock.

Key Headlines Impacting Prenetics Global

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: IM8 reported 288% year-over-year revenue growth in the second quarter and Prenetics raised its FY 2026 IM8 revenue guidance to $220 million–$230 million. The company also initiated FY 2027 revenue guidance of at least $400 million, signaling strong expected demand and expansion. IM8 Q2 revenue growth and guidance article
• Positive Sentiment: Prenetics announced actress and producer Lily Collins as IM8’s global ambassador and a shareholder. Her audience of more than 33 million social-media followers could broaden IM8’s reach beyond elite sports and improve its access to female consumers. The company said it has already achieved positive consolidated adjusted free cash flow and expects to remain positive in the third quarter. Lily Collins IM8 partnership article
• Neutral Sentiment: Analyst forecasts are mixed. Sidoti raised its Q3 and Q4 2026 estimates but still projects a FY 2026 loss of $2.36 per share, while Zacks lowered its Q3 2026 and FY 2026 forecasts but expects stronger Q4 results and a narrower Q1 2027 loss. These revisions suggest near-term volatility as investors assess whether IM8’s growth can translate into sustained profitability.
• Negative Sentiment: Sidoti lowered its FY 2027 EPS forecast to a loss of $0.72 from a loss of $0.60 and reduced several 2027 quarterly estimates. Prenetics’ latest quarter also showed a negative net margin, and revenue was below consensus despite an EPS beat, underscoring execution and profitability concerns.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.